Overview

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Status:
Terminated

Trial end date:
2017-10-03

Target enrollment:

Participant gender:

Summary

The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.

Phase:

Phase 3

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies
Azacitidine
Decitabine